The Pharma Data

JANUARY 3, 2021

04, 2021 (GLOBE NEWSWIRE) — Passage Bio , Inc. Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that U.S. GM1 is a rare and often life-threatening CNS disorder with no approved disease-modifying therapies available.

Therapies 52

Therapies FDA Treatment Clinical Trials 52

The Pharma Data

JANUARY 27, 2021

– Second Product Candidate Expected to Enter Clinic in First Half of 2021. Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal Dementia with Granulin (GRN) Mutations, a Devastating, Progressive Disorder Impacting Adults with No Approved Disease-Modifying Therapy Options. PHILADELPHIA, Jan.

Therapies 52

Therapies Treatment Clinical Trials FDA 52

The Pharma Data

JANUARY 6, 2021

7, 2021 /PRNewswire/ — OyaGen, Inc. A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ ’ (2021) Viruses 13:52 [link]. ROCHESTER, N.Y. , Bennett et al., About OYA1. OYA1 (a.k.a.

Virus 40

Virus Clinical Trials Government Laboratories 40

The Pharma Data

JANUARY 17, 2021

The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease. There is significant unmet medical need for a sustained therapy to treat eye diseases. MUNICH, Germany, Jan.

Therapies 40

Therapies Research Virus Disease 40

The Pharma Data

MARCH 2, 2021

(Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th Conference on Retroviruses and Opportunistic Infections ( virtual CROI 2021) taking place from March 6-10. HIV Research. HCV Research. COVID-19 Research.

Virus 40

Virus Treatment Science Trials 40

The Pharma Data

JANUARY 6, 2021

Process development and quality control will begin in 2021, and full manufacturing capabilities at the 88,000-square-foot facility will be available in 2023. In addition to its lead program, which began Phase I testing in 2020, the company expects to nominate three clinical candidates in 2021.

Virus 52

Virus FDA Approval Clinical Trials Trials 52

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccine 52

Vaccine Trials Virus RNA 52

Agency IQ

FEBRUARY 12, 2024

BY RACHEL COE, MSC | FEB 7, 2024 10:21 PM CST The Bespoke Gene Therapy Consortium A collaborative effort, the Bespoke Gene Therapy Consortium (BGTC) was launched in October 2021 to “accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease.”

FDA 40

FDA Therapies Clinical Trials Disease 40

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

DECEMBER 2, 2020

MTX-COVAB was also found to have virus neutralizing potency (IC50= 40pM), which is comparable or better to that of the leading antibody therapies in development, and cross-neutralizes all clinically relevant virus mutants. MTX-COVAB is a fully human antibody isolated from clinically selected convalescent COVID-19 patients.

Disease 52

Disease Virus Treatment Therapies 52

The Pharma Data

SEPTEMBER 30, 2021

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. As prior work with other respiratory pathogens like influenza has shown, sterilizing immunity to virus re-infection requires adaptive immune responses within the tract and therefore the lung. Breathe in, exhale. doi: 10.1016/j.isci.2021.103037.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

JANUARY 31, 2021

1, 2021 12:05 UTC. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS). IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden.

Immune Response 52

Immune Response Research Therapies Disease 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. Posted: January 2021. Source: AstraZeneca . Source link.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. Posted: January 2021. Source: AstraZeneca. Source link.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

NOVEMBER 23, 2020

Studies funded by a number of grants in the beginning of May are already providing insight into why the virus seems to affect the cardiac system, Lloyd-Jones said. ” COVID-19 was also a major focus of this year’s meeting. ” COVID-19 was also a major focus of this year’s meeting.

Research 52

Research Virus Therapies Trials 52

The Pharma Data

OCTOBER 28, 2020

In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

NOVEMBER 22, 2020

They believe they will have a capacity of up to 3 billion doses in 2021 on a rolling basis, pending regulatory approval. They use mRNA that codes for the spike protein in the SARS-CoV-2 virus, which is embedded in a nanolipid particle—basically a minuscule fat molecule. Trials are also being run in the U.S., Featured Jobs on BioSpace.

Vaccine 52

Vaccine Virus Trials Regulations 52

The Pharma Data

APRIL 15, 2022

These data reinforce the potential function of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group. The neutralizing GMT against the wild-type virus was 2153 (after three doses), compared to 335 after two doses. About Pfizer: Breakthroughs That Change Patients’ Lives.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

MAY 4, 2021

Posted 04 May 2021 | By Michael Mezher . WHO is closely monitoring 10 Covid variants as virus mutates around the world ( CNBC ) . Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries ( Press ). In Focus: US. NYTimes ).

Vaccine 52

Vaccine FDA Approval FDA Licensing 52

The Pharma Data

DECEMBER 3, 2020

Clover intends to initiate a separate pivotal clinical trial of the S-Trimer vaccine candidate in combination with Dynavax’s advanced CpG 1018 adjuvant plus alum in the first half of 2021. Additionally, Clover is leveraging its in-house GMP biomanufacturing capabilities to support large-scale production of its biologic therapies.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

JANUARY 24, 2021

Theralase is focused on its target of enrolling and treating 11 additional patients in early 2021 for a total of 25 patients for potential Breakthrough Designation Approval and approximately 100 patients in 2021 / 2022.” There are 3 pending US clinical study sites that are expected to receive site IRB approval in 1Q2021.

Pharmaceutical Companies 52

Pharmaceutical Companies Virus Clinical Research Pharmaceuticals 52

The Pharma Data

JANUARY 31, 2021

1, 2021 /PRNewswire/ — AIkido Pharma Inc. Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. The key component of Convergent’s PRRT prostate cancer therapy is its proprietary drug, CONV 01-?,

Small Molecule 40

Small Molecule FDA Approval Trials Therapies 40

The Pharma Data

NOVEMBER 23, 2020

The Company is making rapid progress in manufacturing with a capacity of up to 3 billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body. AstraZeneca.

Vaccine 52

Vaccine Virus Trials Clinical Trials 52

The Pharma Data

OCTOBER 27, 2021

. “The main finding in our study is that the equine hyperimmune globulins antibodies developed against the spike protein of the ancestral SARS-CoV-2 had high neutralizing action against the new variants of the virus, such as the gamma strain. iScience, 2021. doi: 10.1016/j.isci.2021.103315. 2021.103315. Source link: [link].

Clinical Trials 52

Clinical Trials Virus Production Treatment 52

The Pharma Data

NOVEMBER 1, 2020

BD expects the order to be fulfilled by June 2021. The BD Veritor Plus System is already in use across Europe to detect Influenza A+B, Respiratory Syncytial Virus (RSV), and Group A Strep. This is the first government contract in Europe for this test, which was CE marked to the IVD Directive (98/79/EC) in September.

Laboratories 52

Laboratories Virus FDA Government 52

The Pharma Data

MARCH 1, 2022

We look forward to discussing this further with FDA over the coming months so that we can make this investigational new therapy available to people living with multidrug-resistant HIV as soon as possible,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

FDA 52

FDA Treatment Science Therapies 52

The Pharma Data

OCTOBER 16, 2020

Novan has been evaluating the ability of its NITRICIL platform technology as a potential nasal treatment option for Covid-19, announcing its potential efficacy as an antiviral against SARS-CoV-2, the virus that causes Covid-19. Source link.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

The Pharma Data

DECEMBER 17, 2020

About casirivimab and imdevimab Casirivimab and imdevimab (formerly known as REGN-COV2 or REGEN-COV2) is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. who require oxygen therapy due to COVID-19, OR.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

Broad Institute

MAY 14, 2025

Because its small size simplifies delivery to cells, NovaIscBs developers say it is a promising candidate for developing gene therapies to treat or prevent disease. Compact tools NovaIscB is derived from a bacterial DNA cutter that belongs to a family of proteins called IscBs, which Zhangs lab discovered in 2021.

Engineering 59

Engineering DNA RNA Therapies 59

The Pharma Data

SEPTEMBER 5, 2021

” These findings were presented at the European Respiratory Society (ERS) International Congress 2021 between September 5-8. Results from the NAVIGATOR Phase 3 trial were published in the New England Journal of Medicine in May 2021. 2,3 Tezepelumab is being developed by Amgen in collaboration with AstraZeneca.

Trials 52

Trials Clinical Trials Therapies Treatment 52

The Pharma Data

AUGUST 30, 2021

Pulmonary infection with the SARS-CoV2 virus can progress to acute respiratory distress syndrome (ARDS), in which inflammation and neutrophil hyperactivation play a central role. There is currently a lack of therapies for ARDS associated with COVID-19. Metoprolol in Critically Ill Patients With COVID-19. J Am Coll Cardiol. 2021.07.003.

Clinical Trials 52

Clinical Trials Drugs Trials Hospitals 52

The Pharma Data

DECEMBER 30, 2020

31, 2020 /PRNewswire/ — ImmVira Group Company (“the Company”), a biotechnology platform dedicated to the development of oncolytic virus(“OV”) and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C financing.

Virus 40

Virus International Trials Clinical Trials 40

The Pharma Data

DECEMBER 30, 2020

AstraZeneca is working with its global partners to continue building manufacturing capacity of up to three billion doses of the vaccine globally in 2021 on a rolling basis, pending regulatory approvals.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

AUGUST 22, 2021

Many of the elderly patients who survived the virus were poor: not exactly the demographic you would expect to fare well in a health crisis. The team’s analysis, which appeared in the journal Signal Transduction & Targeted Therapy (from the Nature publishing group), showed that the data supported findings from other smaller-scale studies.

Doctors 52

Doctors Drugs Immune Response Virus 52

The Pharma Data

SEPTEMBER 9, 2020

billion doses by the end of 2021. BNT162b2 encodes an optimized SARS-CoV-2 full-length spike glycoprotein (S), which is the target of virus neutralizing antibodies. billion doses by the end of 2021. billion doses by the end of 2021. About the Phase 2/3 Study. About Pfizer: Breakthroughs That Change Patients’ Lives.

Vaccine 52

Vaccine Clinical Trials Trials Government 52